Compare Global X MSCI Argentina ETF (ARGT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs TG Therapeutics Inc — how do they compare? Global X MSCI Argentina ETF trades at $91.07, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). Which is the better fit depends on your goals.
| ARGT | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $59.06 |
52-Week Low | $67.55 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT, the Global X MSCI Argentina ETF, trades at $91.13, down 2.46% on the day, with a bearish technical signal from moving averages. Recent news highlights Argentina's economic reforms under the Milei administration as a potential catalyst. The ETF's valuation is noted as attractive relative to historical averages, though key financial ratios are not currently available in the provided data.
The outlook hinges on Argentina's continued economic stabilization. Upside potential exists if reforms sustain, but significant risks include political volatility and the ETF's heavy concentration in a few holdings like MercadoLibre, which could amplify losses if sentiment sours.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
